MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement

Executive Summary

• MedX Health Corp. completed the Initial Closing of its non‑brokered private placement, issuing 7,033,000 units and raising $527,500 in cash.
• The placement targets up to 33,333,334 units at $0.075 per unit for a maximum raise of $2.5 million; further closings are anticipated.
• Closing date for the full placement has been extended to November 7, 2025, and proceeds will fund development of the SIAscopy®/DermSecure® telemedicine platform, expansion into occupational health, and general corporate purposes.

Key Details

• Initial Closing: 7,033,000 units issued; cash proceeds of $527,500. No commissions paid; no Agent’s Warrants issued for this closing.
• Unit Composition: Each unit = 1 fully‑paid common share + ½ Share Purchase Warrant (exercisable at $0.10 per share).
• Maximum Offering Size: Up to 33,333,334 units at $0.075 per unit → up to $2,500,000 gross proceeds.
• Warrant Terms: Each whole Share Purchase Warrant allows purchase of one additional common share at $0.10; exercisable for one year from issuance.
• Agent Compensation (for future closings): 8% cash commission on gross proceeds plus Agent’s Warrants equal to 8% of subscriptions introduced; Agent’s Warrants priced at CAD $0.09 per unit and include a non‑transferable share purchase warrant exercisable at CAD $0.10.
• Regulatory Hold: Securities subject to a four‑month‑plus‑one‑day hold period from issuance date.
• Closing Extension: Ultimate closing date extended to November 7, 2025 pending TSX‑V acceptance; conditional acceptance already received.
• Use of Proceeds: Development of SIAscopy® on DermSecure® platform, launch into occupational health market, and general corporate purposes.
• Insider Participation: Anticipated participation by certain insiders under exemption from formal valuation and minority shareholder approval (MI‑61‑101).

Notable Quotes

• John Gevisser, CEO – MedX Health Corp.: “The successful initial closing of our private placement provides essential capital to accelerate the commercialization of our SIAscopy® technology and expand into new market segments, positioning MedX for sustained growth.”